Principal Investigator
Camillo Ricordi
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20200966
Clinical Trial Summary
Vertex Pharmaceuticals Incorporated - VX20-880-101, A Master Protocol to Evaluate the Safety, Tolerability, and Efficacy of Islet Cell Replacement Therapies in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia: A Phase 1/2/3 Study of VX-880 and a Phase 1/2 Study of VX-017 (Pro00046869)
Phase
Phase I/II
Funding Agency/Sponsor
Industry
Disease
Other